Synergy against fungal pathogens: Working together is better than working alone

Current Medicinal Chemistry

Volumn 21, Issue 7, 2014, Pages 870-893

  Musiol, R ^a   Mrozek Wilczkiewicz, A ^a   Polanski, J ^a  

^a UNIVERSITY OF SILESIA   (Poland)

Author keywords

Antifungals; Azoles; Drug combination; Drug resistance; Mycoses; Synergy

Indexed keywords

ALLYLAMINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CICLOPIROX; CITRONELLOL; ECONAZOLE; EFUNGUMAB; ESSENTIAL OIL; EUGENOL; FLUCONAZOLE; FLUCYTOSINE; FLUINDOSTATIN; GERANIOL; HONOKIOL; IBUPROFEN; ITRACONAZOLE; KETOCONAZOLE; METHYLEUGENOL; METRONIDAZOLE; MICAFUNGIN; NEOLIGNAN; NIKKOMYCIN Z; POSACONAZOLE; RAVUCONAZOLE; RIFAMPICIN; TERBINAFINE; TRICLOSAN; UNINDEXED DRUG; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; DRUG POTENTIATION; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; MYCOSIS; NONHUMAN; PATHOGENESIS; ANTIFUNGAL THERAPY; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DRUG DESIGN; DRUG DETERMINATION; DRUG INTERACTION; HUMAN; MATHEMATICAL MODEL; POLYPHARMACOLOGY; REVIEW;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FUNGI; HUMANS; MODELS, THEORETICAL; MYCOSES;

EID: 84893597003     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666131218094848     Document Type: Article

References (293)

1. Fraser, T. R. An experimental research on the antagonism between the action of physostigma and atropia. Proc. R Soc. Edin., 1871, 7, 506-511.
2. Bindslev, N. Drug-Acceptor Interactions; CoAction publishing, 2009.
3. Loewe S., M. H. Uber Kombinationswirkungen I. Mitteilung: Hilfsmittel der Fragestellung. Arch. Exp. Path. Pharmakol., 1926, 114, 313-326.
4. Bliss, C. I. The toxicity of poisons applied jointly. Ann. Appl. Biol., 1939, 26, 585-615.
5. Gessner, P. K.; Cabana, B. E. A study of the interaction of the hypnotic effects and of the toxic effects of chloral hydrate and ethanol. J. Pharmacol. Exp. Ther., 1970, 174, 247-259.
6. Houy, N. Evolution of cooperation with similarity to an archetype. J. Theor. Biol., 2013, 332, 78-88.
7. Traag, V. A.; Van Dooren, P.; De Leenheer, P. Dynamical models explaining social balance and evolution of cooperation. PLoS One, 2013, 8, e60063.
8. Marcoux, M.; Lusseau, D. Network modularity promotes cooperation. J. Theor. Biol., 2013, 324, 103-108.
9. Hellebrekers, D. M. E. I.; Griffioen, A. W.; van Engeland, M. Dual targeting of epigenetic therapy in cancer. Biochim. Biophys. Acta, 2007, 1775, 76-91.
10. Musiol, R.; Serda, M.; Polanski, J. Prodrugs in photodynamic anticancer therapy. Curr. Pharm. Des., 2011, 17, 3548-3559.
11. http://www.edinformatics.com/biotechnology/antiretroviral-drugs.htm.
12. Boran, A. Systems approaches to polypharmacology and drug discovery. Curr. Opin. Drug Discov. Devel., 2010, 13, 297-309.
13. Peters, J.-U.; Hert, J.; Bissantz, C.; Hillebrecht, A.; Gerebtzoff, G.; Bendels, S.; Tillier, F.; Migeon, J.; Fischer, H.; Guba, W.; Kansy, M. Can we discover pharmacological promiscuity early in the drug discovery process? Drug Discov. Today, 2012, 7-8, 325-335.
14. Tallarida, R. J. Drug synergism: its detection and applications. J. Pharmacol. Exp. Ther., 2001, 298, 865-872.
15. Shafer, S. L.; Hendrickx, J. F. A.; Flood, P.; Sonner, J.; Eger, E. I. Additivity versus synergy: A theoretical analysis of implications for anesthetic mechanisms. Anesth. Analg., 2008, 107, 507-524.
16. Kurin, E.; Nagy, M. Theoretical models for analysis of synergy and antagonism of drugs. Chem. List., 2012, 106, 653-659.
17. Zhao, L.-C.; He, Y.; Deng, X.; Yang, G.-L.; Li, W.; Liang, J.; Tang, Q.-L. Response surface modeling and optimization of accelerated solvent extraction of four lignans from fructus schisandrae. Molecules, 2012, 17, 3618-3629.
18. Goldin, A.; Mantel, N. The employment of combinations of drugs in the chemotherapy of neoplasia: A review. Cancer Res., 1957, 17, 635-654.
19. Ocana, A.; Amir, E.; Yeung, C.; Seruga, B.; Tannock, I. F. How valid are claims for synergy in published clinical studies? Ann. Oncol., 2012, 23, 2161-2166.
20. Chou, T. Drug Combination studies and their synergy quantification using the chou-talalay method drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res., 2010, 70, 440-446.
21. Chou, T. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev., 2006, 58, 621-681.
22. Zhao, L.; Au, J. L.-S.; Wientjes, M. G. Comparison of methods for evaluating drug-drug interaction. Front. Biosci. (Elite Ed.), 2010, 2, 241-249.
23. Anaissie, E.; Bodey, G. P. Nosocomial fungal infections. Old problems and new challenges. Infect. Dis. Clin. North Am., 1989, 3, 867-882.
24. Beck-Sauge, C. M.; Jarvis, W. R. Secular trends in the epidemiology of nosocomial fungal infections in the United States 1980-1990. J. Infect. Dis., 1993, 167, 1247-1251.
25. Nucci, M.; Marr, K. A. Emerging fungal diseases. Clin. Infect. Dis., 2005, 41, 521-526.
26. Bastert, J.; Schaller, M.; Korting, H. C.; Evans, E. G. Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts. Int. J. Antimicrob. Agents, 2001, 17, 81-91.
27. Kauffman, C. A. Zygomycosis: reemergence of an old pathogen. Clin. Infect. Dis., 2004, 39, 588-590.
28. Dodds Ashley, E. S.; Lewis, R.; Lewis, J. S.; Martin, C.; Andes, D. Pharmacology of systemic antifungal agents. Clin. Infect. Dis., 2006, 43, 28-39.
29. Spanakis, E. K.; Aperis, G.; Mylonakis, E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin. Infect. Dis., 2006, 43, 1060-1068.
30. Dismukes, W. E. Antifungal therapy: lessons learned over the past 27 years. Clin. Infect. Dis., 2006, 42, 1289-1296.
31. Sampathkumar, P.; Paya, C. V Fusarium infection after solid-organ transplantation. Clin. Infect. Dis., 2001, 32, 1237-1240.
32. Park, B. J.; Pappas, P. G.; Wannemuehler, K. a; Alexander, B. D.; Anaissie, E. J.; Andes, D. R.; Baddley, J. W.; Brown, J. M.; Brumble, L. M.; Freifeld, A. G.; Hadley, S.; Herwaldt, L.; Ito, J. I.; Kauffman, C. a; Lyon, G. M.; Marr, K. a; Morrison, V. a; Papanicolaou, G.; Patterson, T. F.; Perl, T. M.; Schuster, M. G.; Walker, R.; Wingard, J. R.; Walsh, T. J.; Kontoyiannis, D. P. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg. Infect. Dis., 2011, 17, 1855-1864.
33. Snelders, E.; Camps, S. M. T.; Karawajczyk, A.; Schaftenaar, G.; Kema, G. H. J.; van der Lee, H. A.; Klaassen, C. H.; Melchers, W. J. G.; Verweij, P. E. Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One, 2012, 7, e31801.
34. Trösken, E. R.; Bittner, N.; Völkel, W. Quantitation of 13 azole fungicides in wine samples by liquid chromatography-tandem mass spectrometry. J. Chromatogr. A., 2005, 1083, 113-119.
35. Hof, H. Critical annotations to the use of azole antifungals for plant protection. Antimicrob. Agents Chemother., 2001, 45, 2987-2990.
36. Hof, H. Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine? Drug Resist. Update, 2008, 11, 25-31.
37. Mortensen, K. L.; Mellado, E.; Lass-Flörl, C.; Rodriguez-Tudela, J. L.; Johansen, H. K.; Arendrup, M. C. Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob. Agents Chemother., 2010, 54, 4545-4559.
38. Snelders, E.; van der Lee, H. A. L.; Kuijpers, J.; Rijs, A. J. M. M.; Varga, J.; Samson, R. A.; Mellado, E.; Donders, A. R. T.; Melchers, W. J. G.; Verweij, P. E. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med., 2008, 5, e219.
39. Verweij, P. E.; Snelders, E.; Kema, G. H. J.; Mellado, E.; Melchers, W. J. G. Azole resistance in Aspergillus fumigatus: A side-effect of environmental fungicide use? Lancet Infect. Dis., 2009, 9, 789-795.
40. Mellado, E.; Garcia-Effron, G.; Alcázar-Fuoli, L.; Melchers, W. J. G.; Verweij, P. E.; Cuenca-Estrella, M.; Rodríguez-Tudela, J. L. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother., 2007, 51, 1897-1904.
41. Howard, S. J.; Webster, I.; Moore, C. B.; Gardiner, R. E.; Park, S.; Perlin, D. S.; Denning, D. W. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents, 2006, 28, 450-453.
42. Bueid, A.; Howard, S. J.; Moore, C. B.; Richardson, M. D.; Harrison, E.; Bowyer, P.; Denning, D. W. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother., 2010, 65, 2116-2118.
43. Paluszynski, J. P.; Klassen, R.; Rohe, M.; Meinhardt, F. Various cytosine/adenine permease homologues are involved in the toxicity of 5-fluorocytosine in Saccharomyces cerevisiae. Yeast, 2006, 23, 707-715.
44. Chevallier, M. R.; Jund, R.; Lacroute, F. Characterization of cytosine permeation in Saccharomyces cerevisiae. J. Bacteriol., 1975, 122, 629-641.
45. Schwarz, P.; Janbon, G.; Dromer, F.; Lortholary, O.; Dannaoui, E. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother., 2007, 51, 383-385.
46. Paluszynski, J. P.; Klassen, R.; Meinhardt, F. Genetic prerequisites for additive or synergistic actions of 5-fluorocytosine and fluconazole in baker's yeast. Microbiology, 2008, 154, 3154-3164.
47. Akins, R. A. An update on antifungal targets and mechanisms of resistance in Candida albicans. Med. Mycol., 2005, 43, 285-318.
48. Hill, J. a; Ammar, R.; Torti, D.; Nislow, C.; Cowen, L. E. Genetic and genomic architecture of the evolution of resistance to antifungal drug combinations. PLoS Genet., 2013, 9, e1003390.
49. Geber, A.; Hitchcock, C. A.; Swartz, J. E.; Pullen, F. S.; Marsden, K. E.; Kwon-Chung, K. J.; Bennett, J. E. Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob. Agents Chemother., 1995, 39, 2708-2717.
50. Vale-Silva, L. A.; Coste, A. T.; Ischer, F.; Parker, J. E.; Kelly, S. L.; Pinto, E.; Sanglard, D. Azole resistance by loss of function of the sterol 5,6-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrob. Agents Chemother., 2012, 56, 1960-1968.
51. Morio, F.; Pagniez, F.; Lacroix, C.; Miegeville, M.; Le Pape, P. Amino acid substitutions in the Candida albicans sterol 5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. J. Antimicrob. Chemother., 2012, 67, 2131-2138.
52. Miyazaki, T.; Miyazaki, Y.; Izumikawa, K.; Kakeya, H.; Miyakoshi, S.; Bennett, J. E.; Kohno, S. Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance. Antimicrob. Agents Chemother., 2006, 50, 580-586.
53. Odds, F. Antifungal agents: mechanisms of action. Trends Microbiol., 2003, 11, 272-279.
54. Georgopapadakou, N. H. Antifungals: mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol., 1988, 1, 547-557.
55. Tsimogianni, A. M.; Andrianakis, I.; Betrosian, A.; Douzinas, E. Cardiac arrest provoked by itraconazole and amiodarone interaction: A case report. J. Med. Case Rep., 2011, 5, 333.
56. Said, A.; Garnick, J. J.; Dieterle, N.; Peres, E.; Abidi, M. H.; Ibrahim, R. B. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy, 2006, 26, 289-295.
57. Nicolau, D. P.; Crowe, H. M.; Nightingale, C. H.; Quintiliani, R. Rifampin-fluconazole interaction in critically ill patients. Ann. Pharmacother., 1995, 29, 994-996.
58. Martín, E.; Parras, P.; Lozano, M. C. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole. Chemotherapy, 1992, 38, 335-339.
59. Torrado, J. J.; Espada, R.; Ballesteros, M. P.; Torrado-Santiago, S. Amphotericin B formulations and drug targeting. J. Pharm. Sci., 2008, 97, 2405-2425.
60. Adler-Moore, J. P.; Proffitt, R. T. Amphotericin B lipid preparations: what are the differences? Clin. Microbiol. Infect., 2008, 14 Suppl 4, 25-36.
61. Chamilos, G.; Luna, M.; Lewis, R. E.; Chemaly, R.; Raad, I. I.; Kontoyiannis, D. P. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: A retrospective, nonrandomized autopsy study. Clin. Ther., 2007, 29, 1980-1986.
62. Kuiper, L.; Ruijgrok, E. J. A review on the clinical use of inhaled amphotericin B. J Aerosol. Med. Pulm. Drug Deliv., 2009, 22, 213-227.
63. Gupta, A. K.; Ryder, J. E.; Cooper, E. A. Naftifine: A review. J. Cutan. Med. Surg., 2008, 12, 51-58.
64. Krishnan-Natesan, S. Terbinafine: A pharmacological and clinical review. Expert Opin. Pharmacother., 2009, 10, 2723-2733.
65. Abdel-Rahman, S. M.; Nahata, M. C. Oral terbinafine: A new antifungal agent. Ann. Pharmacother., 1997, 31, 445-456.
66. Favre, B.; Ryder, N. S. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob. Agents Chemother., 1996, 40, 443-447.
67. Urbina, J. A.; Lazardi, K.; Aguirre, T.; Piras, M. M.; Piras, R. Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on Epimastigotes and Amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother., 1988, 32, 1237-1242.
68. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard - Second Edition Serving the World ' s Medical Science Community Through Voluntary Consensus; Vol. 22.
69. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard - Second Edition. 28.
70. Method for Antifungal Disk Diffusion Susceptibility Testing of Nondermatophyte Filamentous Fungi; Approved Guideline. CLSI Doc. M51-A, 2010, 30.
71. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline. NCCLS Doc. M44-A, 2004, 24.
72. Moody, J. A. Synergy testing: broth microdilution checkerboard and broth macrodilution methods. In Clinical microbiology procedures handbook. H.D. Eisenberg, Ed.; American Society for Microbiology, Washington, DC, 1992; p 5.18.1-5.18.23.
73. Orhan, G.; Bayram, A.; Zer, Y.; Balci, I. Synergy Tests by E Test and Checkerboard Methods of Antimicrobial Combinations against Brucella melitensis. J. Clin. Microbiol., 2005, 43, 140-143.
74. White, R. L.; Burgess, D. S.; Manduru, M.; Bosso, J. A.; White, R. L.; Burgess, D. S.; Manduru, M.; Bosso, J. A. Comparison of three different in vitro methods of detecting synergy-: Time-kill, checkerboard, and E test. Antimicrob. Agents Chemother., 1996, 40, 1917-1918
75. Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline M26-A, 1999, Vol. 19, No.18, NCCLS.
76. Mayrhofer, S.; Domig, K. J.; Mair, C.; Zitz, U.; Huys, G.; Kneifel, W. Comparison of broth microdilution, Etest, and agar disk diffusion methods for antimicrobial susceptibility testing of Lactobacillus acidophilus group members. Appl. Environ. Microbiol., 2008, 74, 3745-3748.
77. Lewis, R. E.; Diekema, D. J.; Messer, S. a; Pfaller, M. a; Klepser, M. E. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J. Antimicrob. Chemother., 2002, 49, 345-351.
78. Bani, S.; Lunder, M. Additive effect of the combination of griseofulvin and ketoconazole against Microsporum canis in vitro. Mycoses, 2009, 32, 487-489.
79. Baran, R.; Feuilhade, M.; Combernale, P.; Datry, A.; Goettmann, S.; Pietrini, P.; Viguie, C.; Badillet, G.; Larnier, C.; Czernielewski, J. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br. J. Dermatol., 2000, 142, 1177-1183.
80. Gupta, A.; Kohli, Y. susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination. Br. J. Dermatol., 2003, 149, 296-305.
81. Argenta, J. S.; Santurio, J. M.; Alves, S. H.; Pereira, D. I. B.; Cavalheiro, A. S.; Spanamberg, A.; Ferreiro, L. In vitro activities of voriconazole, itraconazole, and terbinafine alone or in combination against Pythium insidiosum isolates from Brazil. Antimicrob. Agents Chemother., 2008, 52, 767-769.
82. Krajaejun, T.; Sathapatayavongs, B.; Pracharktam, R.; Nitiyanant, P.; Leelachaikul, P.; Wanachiwanawin, W.; Chaiprasert, A.; Assanasen, P.; Saipetch, M.; Mootsikapun, P.; Chetchotisakd, P.; Lekhakula, A.; Mitarnun, W.; Kalnauwakul, S.; Supparatpinyo, K.; Chaiwarith, R.; Chiewchanvit, S.; Tananuvat, N.; Srisiri, S.; Suankratay, C.; Kulwichit, W.; Wongsaisuwan, M.; Somkaew, S. Clinical and epidemiological analyses of human pythiosis in Thailand. Clin. Infect. Dis., 2006, 43, 569-576.
83. Pupaibool, J.; Chindamporn, A.; Patrakul, K.; Suankratay, C.; Sindhuphak, W.; Kulwichit, W. Human pythiosis. Emerg. Infect. Dis., 2006, 12, 517-518.
84. Rivierre, C.; Laprie, C.; Guiard-Marigny, O.; Bergeaud, P.; Berthelemy, M.; Guillot, J. Pythiosis in Africa. Emerg. Infect. Dis., 2005, 11, 479-481.
85. Cavalheiro, A. S.; Maboni, G.; de Azevedo, M. I.; Argenta, J. S.; Pereira, D. I. B.; Spader, T. B.; Alves, S. H.; Santurio, J. M. In Vitro activity of terbinafine combined with caspofungin and azoles against Pythium insidiosum. Antimicrob. Agents Chemother., 2009, 53, 2136-2138.
86. Cavalheiro, A. S.; Zanette, R. a; Spader, T. B.; Lovato, L.; Azevedo, M. I.; Botton, S.; Alves, S. H.; Santurio, J. M. In vitro activity of terbinafine associated to amphotericin B, fluvastatin, rifampicin, metronidazole and ibuprofen against Pythium insidiosum. Vet. Microbiol., 2009, 137, 408-411.
87. Balfour, J. A.; Faulds, D. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs, 1992, 43, 259-284.
88. Barchiesi, F.; Di Francesco, L. F.; Compagnucci, P.; Arzeni, D.; Giacometti, A.; Scalise, G. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J. Antimicrob. Chemother., 1998, 41, 59-65.
89. Barchiesi, F.; Falconi Di Francesco, L.; Scalise, G. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob. Agents Chemother., 1997, 41, 1812-1814.
90. Barchiesi, F.; Spreghini, E.; Maracci, M.; Fothergill, A. W.; Baldassarri, I.; Rinaldi, M. G.; Scalise, G.; Ancona, T. In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob. Agents Chemother., 2004, 48, 3317-3322.
91. Perea, S.; Gonzalez, G.; Fothergill, A. W.; Sutton, D. A.; Rinaldi, M. G. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles. J. Clin. Microbiol., 2002, 40, 1831-1833.
92. Weig, M.; Müller, F. M. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother., 2001, 45, 966-968.
93. Gil-Lamaignere, C.; Müller, F.-M. C. Differential effects of the combination of caspofungin and terbinafine against Candida albicans, Candida dubliniensis and Candida kefyr. Int. J. Antimicrob. Agents, 2004, 23, 520-523.
94. Siau, H.; Kerridge, D. The effect of antifungal drugs in combination on the growth of Candida glabrata in solid and liquid media. J. Antimicrob. Chemother., 1998, 41, 357-366.
95. Scheid, L. A.; Alves, D.; Mario, N.; Kubiça, T. F.; Santurio, J. M.; Alves, S. H. In vitro activities of antifungal agents alone and in combination against fluconazole-susceptible and -resistant strains of Candida dubliniensis. Braz. J. Infect. Dis., 2012, 16, 78-81.
96. Chaturvedi, V.; Ramani, R.; Andes, D.; Diekema, D. J.; Pfaller, M. a; Ghannoum, M. a; Knapp, C.; Lockhart, S. R.; Ostrosky-Zeichner, L.; Walsh, T. J.; Marchillo, K.; Messer, S.; Welshenbaugh, A. R.; Bastulli, C.; Iqbal, N.; Paetznick, V. L.; Rodriguez, J.; Sein, T. Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. Antimicrob. Agents Chemother., 2011, 55, 1543-1548.
97. Karlowsky, J. a; Hoban, D. J.; Zhanel, G. G.; Goldstein, B. P. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species. Int. J. Antimicrob. Agents, 2006, 27, 174-177.
98. Fanning, S.; Mitchell, A. P. Fungal biofilms. PLoS Pathog., 2012, 8, e1002585.
99. Chatzimoschou, A.; Katragkou, A.; Simitsopoulou, M.; Antachopoulos, C.; Georgiadou, E.; Walsh, T. J.; Roilides, E. Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells. Antimicrob. Agents Chemother., 2011, 55, 1968-1974.
100. Nishi, I.; Sunada, A.; Toyokawa, M.; Asari, S.; Iwatani, Y. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species. J. Jnfect. Chemother., 2009, 15, 1-5.
101. Tobudic, S.; Kratzer, C.; Lassnigg, A.; Graninger, W.; Presterl, E. In vitro activity of antifungal combinations against Candida albicans biofilms. J. Antimicrob. Chemother., 2010, 65, 271-274.
102. Sabiiti, W.; May, R. C. Mechanisms of infection by the human fungal pathogen Cryptococcus neoformans. Future Microbiol., 2012, 7, 1297-1313.
103. Negroni, R. Cryptococcosis. Clin. Dermatol., 2012, 30, 599-609.
104. Serena, C.; Fernandez-Torres, B.; Pastor, F. J.; Trilles, L.; Lazera, M. d. S.; Nolard, N.; Guarro, J. In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus. Antimicrob. Agents Chemother., 2005, 49, 2994-2996.
105. Santos, J. R. A.; Gouveia, L. F.; Taylor, E. L. S.; Resende-Stoianoff, M. A.; Pianetti, G. A.; César, I. C.; Santos, D. A. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. Antimicrob. Agents Chemother., 2012, 56, 2553-2558.
106. Serena, C.; Mariné, M.; Pastor, F. J.; Nolard, N.; Guarro, J. In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula. J. Antimicrob. Chemother., 2005, 55, 1020-1023.
107. Cooper, C. R.; Haycocks, N. G. Penicillium marneffei: An insurgent species among the penicillia. J. Eukaryot. Microbiol., 2000, 47, 24-28.
108. Ustianowski, A. P.; Sieu, T. P. M.; Day, J. N. Penicillium marneffei infection in HIV. Curr. Opin. Infect. Dis., 2008, 21, 31-36.
109. Cooper, C. R.; Vanittanakom, N. Insights into the pathogenicity of Penicillium marneffei. Future Microbiol., 2008, 3, 43-55.
110. Antinori, S.; Gianelli, E.; Bonaccorso, C.; Ridolfo, A. L.; Croce, F.; Sollima, S.; Parravicini, C. Disseminated Penicillium marneffei infection in an HIV-positive Italian patient and a review of cases reported outside endemic regions. J. Travel. Med., 2006, 13, 181-188.
111. Duong, T. A. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin. Infect. Dis., 1996, 23, 125-130.
112. Cao, C.; Liu, W.; Li, R.; Wan, Z.; Qiao, J. In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of Penicillium marneffei. J. Antimicrob. Chemother., 2009, 63, 340-342.
113. Yu, J.; Li, R.; Zhang, M.; Liu, L.; Wan, Z. In vitro interaction of terbinafine with itraconazole and amphotericin B against fungi causing chromoblastomycosis in China. Med. Mycol., 2008, 46, 745-747.
114. Sun, Y.; Liu, W.; Wan, Z.; Wang, X.; Li, R. Antifungal activity of antifungal drugs, as well as drug combinations against Exophiala dermatitidis. Mycopathologia, 2011, 171, 111-7.
115. Cuenca-Estrella, M.; Gomez-Lopez, A.; Mellado, E.; Buitrago, M. J.; Monzón, A.; Rodriguez-Tudela, J. L. Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents. Antimicrob. Agents Chemother., 2003, 47, 2339-2341.
116. Cuenca-Estrella, M.; Gomez-Lopez, A.; Buitrago, M. J.; Mellado, E.; Garcia-Effron, G.; Rodriguez-Tudela, J. L. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob. Agents Chemother., 2006, 50, 2248-2250.
117. Zhang, J.-M.; Xi, L.-Y.; Zhang, H.; Xie, Z.; Sun, J.-F.; Li, X.-Q.; Lu, S. Synergistic effects of terbinafine and itraconazole on clinical isolates of Fonsecaea monophora. Eur. J. Dermatol., 2009, 19, 451-455.
118. Zhang, J.; Xi, L.; Lu, C.; Li, X.; Xie, T.; Zhang, H.; Xie, Z.; De Hoog, S. Successful treatment for chromoblastomycosis caused by Fonsecaea monophora: A report of three cases in Guangdong, China. Mycoses, 2009, 52, 176-181.
119. Zhang, X.; Huang, H.; Feng, P.; Zhang, J.; Zhong, Y.; Xue, R.; Xie, Z.; Li, M.; Xi, L. In vitro activity of itraconazole in combination with terbinafine against clinical strains of itraconazole-insensitive Sporothrix schenckii. Eur. J. Dermatol., 2011, 21, 573-576.
120. Ribes, J. A.; Vanover-Sams, C. L.; Baker, D. J. Zygomycetes in human disease. Clin. Microb. Rev., 2000, 13, 236-301.
121. Dannaoui, E.; Afeltra, J.; Meis, J. F. G. M.; Verweij, P. E. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob. Agents Chemother., 2002, 46, 2708-2711.
122. Gómez-López, A.; Cuenca-Estrella, M.; Mellado, E.; Rodríguez-Tudela, J. L. In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota. Antimicrob. Agents Chemother., 2003, 45, 199-202.
123. Arikan, S.; Sancak, B.; Alp, S.; Hascelik, G.; McNicholas, P. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med. Mycol., 2008, 46, 567-573.
124. Perkhofer, S.; Locher, M.; Cuenca-Estrella, M.; Rüchel, R.; Würzner, R.; Dierich, M. P.; Lass-Flörl, C. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro. Antimicrob. Agents Chemother., 2008, 52, 2636-2638.
125. Rodríguez, M. M.; Serena, C.; Mariné, M.; Pastor, F. J.; Guarro, J. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob. Agents Chemother., 2008, 52, 3786-3788.
126. Guembe, M.; Guinea, J.; Peláez, T.; Torres-Narbona, M.; Bouza, E. Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob. Agents Chemother., 2007, 51, 3457-8345.
127. Córdoba, S.; Rodero, L.; Vivot, W.; Abrantes, R.; Davel, G.; Vitale, R. G. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int. J. Antimicrob. Agents, 2008, 31, 171-174.
128. Li, L.; Wang, Z.; Li, R.; Luo, S.; Sun, X. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients. Am. J. Ophthalmol., 2008, 146, 724-728.
129. Song, M. J.; Lee, J. H.; Lee, N. Y. Fatal Scedosporium prolificans infection in a paediatric patient with acute lymphoblastic leukaemia. Mycoses, 2011, 54, 81-83.
130. Tintelnot, K.; Just-Nübling, G.; Horré, R.; Graf, B.; Sobottka, I.; Seibold, M.; Haas, A.; Kaben, U.; De Hoog, G. S. A review of German Scedosporium prolificans cases from 1993 to 2007. Med. Mycol., 2009, 47, 351-358.
131. Rodriguez-Tudela, J. L.; Berenguer, J.; Guarro, J.; Kantarcioglu, A. S.; Horre, R.; de Hoog, G. S.; Cuenca-Estrella, M. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med. Mycol., 2009, 47, 359-370.
132. Gosbell, I. B.; Toumasatos, V.; Yong, J.; Kuo, R. S.; Ellis, D. H.; Perrie, R. C. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses, 2003, 46, 233-236.
133. Howden, B. P.; Slavin, M. A.; Schwarer, A. P.; Mijch, A. M. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur. J. Clin. Microbiol. Infect. Dis., 2003, 22, 111-113.
134. Meletiadis, J.; Mouton, J.; Meis, J. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother., 2003, 47, 106-117.
135. Greco, W. R.; Bravo, G.; Parsons, J. C. The search for synergy: A critical review from a response surface perspective. Pharmacol. Rev., 1995, 47, 331-385.
136. Kirkpatrick, W. R.; Vallor, A. C.; McAtee, R. K.; Ryder, N. S.; Fothergill, A. W.; Rinaldi, M. G.; Patterson, T. F. Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis. Antimicrob. Agents Chemother., 2005, 49, 4751-4753.
137. Biancalana, F. S. C.; Lyra, L.; Moretti, M. L.; Schreiber, A. Z. Susceptibility testing of terbinafine alone and in combination with amphotericin B, itraconazole, or voriconazole against conidia and hyphae of dematiaceous molds. Antimicrob. Agents Chemother., 2011, 71, 378-385.
138. Demchok, J. P.; Meletiadis, J.; Roilides, E.; Walsh, T. J. Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp. Mycoses, 2010, 53, 239-245.
139. Manavathu, E. K.; Alangaden, G. J.; Chandrasekar, P. H. Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus. J. Antimicrob. Chemother., 2003, 51, 1423-1425.
140. Calvo, E.; Pastor, F. J.; Salas, V.; Mayayo, E.; Guarro, J. Combined therapy of voriconazole and anidulafungin in murine infections by Aspergillus flavus. Mycopathologia, 2012, 173, 251-257.
141. Perkhofer, S.; Lass-Flörl, C. Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination. Expert. Opin. Investig. Drugs, 2009, 18, 1393-1404.
142. Krishnan-Natesan, S.; Chandrasekar, P. H.; Manavathu, E. K.; Revankar, S. G. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine. Diagn Microbiol. Infect. Dis., 2008, 62, 443-446.
143. Hector, R. F.; Rutherford, G. W.; Tsang, C. A.; Erhart, L. M.; McCotter, O.; Anderson, S. M.; Komatsu, K.; Tabnak, F.; Vugia, D. J.; Yang, Y.; Galgiani, J. N. The public health impact of coccidioidomycosis in Arizona and California. Int. J. Environ. Res. Public Health, 2011, 8, 1150-1173.
144. Bisser, S. R.; Weiss, E. C. Increase in Coccidioidomycosis -California, 2000-2007. MMWR. Morb. Mortal Wkly. Rep., 2009, 58, 105-109.
145. Chaudhary, P. M.; Tupe, S. G.; Deshpande, M. V Chitin synthase inhibitors as antifungal agents. Mini Rev. Med. Chem., 2013, 2, 222-236.
146. Galgiani, J. N. Coccidioidomycosis: changing perceptions and creating opportunities for its control. Ann. N. Y. Acad. Sci., 2007, 1111, 1-18.
147. Li, R. K.; Rinaldi, M. G. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob. Agents Chemother., 1999, 43, 1401-1405.
148. Hector, R. F.; Davidson, A. P.; Johnson, S. M. Comparison of susceptibility of fungal isolates to lufenuron and nikkomycin Z alone or in combination with itraconazole. Am. J. Vet. Res., 2005, 66, 1090-1103.
149. Sandovsky-Losica, H.; Shwartzman, R.; Lahat, Y.; Segal, E. Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B. J. Antimicrob. Chemother., 2008, 62, 635-637.
150. Chiou, C. C.; Mavrogiorgos, N.; Tillem, E.; Hector, R.; Walsh, T. J. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob. Agents Chemother., 2001, 45, 3310-3321.
151. Ganesan, L. T.; Manavathu, E. K.; Cutright, J. L.; Alangaden, G. J.; Chandrasekar, P. H. In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus. Clin. Microbiol. Infect., 2004, 10, 961-966.
152. Tariq, V. N.; Scott, E. M.; McCain, N. E. Use of decimal assay for additivity to demonstrate synergy in pair combinations of econazole, nikkomycin Z, and ibuprofen against Candida albicans in vitro. Antimicrob. Agents Chemother., 1995, 39, 2615-2619.
153. Cruz, M. C.; Goldstein, A. L.; Blankenship, J. R.; Del Poeta, M.; Davis, D.; Cardenas, M. E.; Perfect, J. R.; McCusker, J. H.; Heitman, J. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J., 2002, 21, 546-559.
154. Del Poeta, M.; Cruz, M. C.; Cardenas, M. E.; Perfect, J. R.; Heitman, J. Synergistic Antifungal Activities of Bafilomycin A1, Fluconazole, and the Pneumocandin MK-0991/Caspofungin Acetate (L-743,873) with Calcineurin Inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob. Agents Chemother., 2000, 44, 739-746.
155. Onyewu, C.; Blankenship, J. R.; Del Poeta, M.; Heitman, J. Ergosterol Biosynthesis Inhibitors Become Fungicidal when Combined with Calcineurin Inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob. Agents Chemother., 2003, 47, 956-964.
156. Cowen, L. E.; Lindquist, S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science, 2005, 309, 2185-2189.
157. Cowen, L. E. The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nat. Rev. Microbiol., 2008, 6, 187-198.
158. Heitman, J. Cell biology. A fungal Achilles' heel. Science, 2005, 309, 2175-2176.
159. White, T. C.; Marr, K. A.; Bowden, R. A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev., 1998, 11, 382-402.
160. Robbins, N.; Uppuluri, P.; Nett, J.; Rajendran, R.; Ramage, G.; Lopez-Ribot, J. L.; Andes, D.; Cowen, L. E. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog., 2011, 7, e1002257.
161. Assessment report for Mycograb, European Medicines Agency, Procedure no. EMEA/H/C658; 2007.
162. Matthews, R. C.; Rigg, G.; Hodgetts, S.; Carter, T.; Chapman, C.; Gregory, C.; Illidge, C.; Burnie, J. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother., 2003, 47, 2208-2216.
163. Nooney, L.; Matthews, R. C.; Burnie, J. P. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn. Microbiol. Infect. Dis., 2005, 51, 19-29.
164. Matthews, R. C.; Burnie, J. P. Recombinant antibodies: A natural partner in combinatorial antifungal therapy. Vaccine, 2004, 22, 865-871.
165. Burnie, J.; Matthews, R. Genetically recombinant antibodies: new therapeutics against candidiasis. Expert Opin. Biol. Ther., 2004, 4, 233-241.
166. Hodgetts, S.; Nooney, L.; Al-Akeel, R.; Curry, A.; Awad, S.; Matthews, R.; Burnie, J. Efungumab and caspofungin: pre-clinical data supporting synergy. J. Antimicrob. Chemother., 2008, 61, 1132-1139.
167. Krenova, Z.; Pavelka, Z.; Lokaj, P.; Skotakova, J.; Kocmanova, I.; Teyschl, O.; Kren, L.; Mudry, P.; Sterba, J. Successful treatment of life-threatening Candida peritonitis in a child with abdominal non-Hodgkin lymphoma using Efungumab and amphotericin B colloid dispersion. J. Pediatr. Hematol. Oncol., 2010, 32, 128-30.
168. Sutherland, A.; Ellis, D. Treatment of a critically ill child with disseminated Candida glabrata with a recombinant human antibody specific for fungal heat shock protein 90 and liposomal amphotericin B, caspofungin, and voriconazole. Pediatr. Crit. Care Med., 2008, 9, e23-25.
169. Bugli, F.; Cacaci, M.; Martini, C.; Torelli, R.; Posteraro, B.; Sanguinetti, M.; Paroni Sterbini, F. Human monoclonal antibodybased therapy in the treatment of invasive candidiasis. Clin. Dev. Immunol., 2013, 2013, 403121.
170. Richie, D. L.; Ghannoum, M. a; Isham, N.; Thompson, K. V; Ryder, N. S. Nonspecific effect of Mycograb on amphotericin B MIC. Antimicrob. Agents Chemother., 2012, 56, 3963-3964.
171. Moragues, M. D.; Omaetxebarria, M. J.; Elguezabal, N.; Sevilla, M. J.; Conti, S.; Polonelli, L.; Pontón, J. A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect. Immun., 2003, 71, 5273-5279.
172. Lee, J.-H.; Jang, E.-C.; Han, Y. Combination immunotherapy of MAb B6.1 with fluconazole augments therapeutic effect to disseminated candidiasis. Arch. Pharm. Res., 2011, 34, 399-405.
173. Mizutani, S.; Endo, M.; Ino-Ue, T.; Kurasawa, M.; Uno, Y.; Saito, H.; Kato, I.; Takesako, K. Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infections. Antimicrob. Agents Chemother., 2000, 44, 243-247.
174. Stevens, D. A.; Kullberg, B. J.; Brummer, E.; Casadevall, A.; Netea, M. G.; Sugar, A. M. Combined treatment: Antifungal drugs with antibodies, cytokines or drugs. Med. Mycol., 2000, 38 Suppl 1, 305-315.
175. Martinez, L. R.; Christaki, E.; Casadevall, A. Specific antibody to Cryptococcus neoformans glucurunoxylomannan antagonizes antifungal drug action against cryptococcal biofilms in vitro. J. Infect. Dis., 2006, 194, 261-266.
176. Roll, A.; Cozzio, A.; Fischer, B.; Schmid-Grendelmeier, P. Microbial colonization and atopic dermatitis. Curr. Opin. Allergy Clin. Immunol., 2004, 4, 373-378.
177. Burkhart, C. G.; Burkhart, C. N.; Isham, N. Synergistic antimicrobial activity by combining an allylamine with benzoyl peroxide with expanded coverage against yeast and bacterial species. Br. J. Dermatol., 2006, 154, 341-344.
178. Campbell, L.; Zirwas, M. J. Triclosan. Dermatitis, 2006, 17, 204-207.
179. Yu, L.; Ling, G.; Deng, X.; Jin, J.; Jin, Q.; Guo, N. In vitro interaction between fluconazole and triclosan against clinical isolates of fluconazole-resistant Candida albicans determined by different methods. Antimicrob. Agents Chemother., 2011, 55, 3609-3612.
180. Miceli, M. H.; Bernardo, S. M.; Lee, S. A. In vitro analyses of the combination of high-dose doxycycline and antifungal agents against Candida albicans biofilms. Int. J. Antimicrob. Agents, 2009, 34, 326-332.
181. Fiori, A.; Van Dijck, P. Potent synergistic effect of doxycycline with fluconazole against Candida albicans is mediated by interference with iron homeostasis. Antimicrob. Agents Chemother., 2012, 56, 3785-3796.
182. Ku, T. S. N.; Palanisamy, S. K. A.; Lee, S. A. Susceptibility of Candida albicans biofilms to azithromycin, tigecycline and vancomycin and the interaction between tigecycline and antifungals. Int. J. Antimicrob. Agents, 2010, 36, 441-446.
183. Beggs, W. H.; Sarosi, G. A.; Walker, M. I. Synergistic action of amphotericin B and rifampin against Candida species. J. Infect. Dis., 1976, 133, 206-209.
184. Kobayashi, G. S.; Cheung, S.-S. C.; Schlessinger, D.; Medoff, G. Effects of rifamycin derivatives, alone and in combination with Amphotericin B, Against Histoplasma capsulatum. Antimicrob. Agents Chemother., 1974, 5, 16-18.
185. Fujita, N. K.; Edwards, J. E. Combined in vitro effect of amphotericin B and rifampin on Cryptococcus neoformans. Antimicrob. Agents Chemother., 1981, 19, 196-198.
186. Edwards, J. E.; Morrison, J.; Henderson, D. K.; Montgomerie, J. Z. Combined effect of amphotericin B and rifampin on Candida species. Antimicrob. Agents Chemother., 1980, 17, 484-487.
187. Hughes, C. E.; Harris, C.; Moody, J. A.; Peterson, L. R.; Gerding, D. N. In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp. Antimicrob. Agents Chemother., 1984, 25, 560-562.
188. Clancy, C. J.; Yu, Y. C.; Lewin, A.; Nguyen, M. H. Inhibition of RNA synthesis as a therapeutic strategy against Aspergillus and Fusarium: demonstration of in vitro synergy between rifabutin and amphotericin B. Antimicrob. Agents Chemother., 1998, 42, 509-513.
189. Zhai, B.; Zhou, H.; Yang, L.; Zhang, J.; Jung, K.; Giam, C.-Z.; Xiang, X.; Lin, X. Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J. Antimicrob. Chemother., 2010, 65, 931-938.
190. Cury, A. E.; Hirschfeld, M. P. Interactions between amphotericin B and nitroimidazoles against Candida albicans. Mycoses, 1997, 40, 187-192.
191. Belter, A.; Skupinska, M.; Giel-Pietraszuk, M.; Grabarkiewicz, T.; Rychlewski, L.; Barciszewski, J. Squalene monooxygenase -A target for hypercholesterolemic therapy. Biol. Chem., 2011, 392, 1053-1075.
192. Charlton-Menys, V.; Durrington, P. N. Squalene synthase inhibitors-: clinical pharmacology and cholesterol-lowering potential. Drugs, 2007, 67, 11-16.
193. Chugh, A.; Ray, A.; Gupta, J. B. Squalene epoxidase as hypocholesterolemic drug target revisited. Prog. Lipid. Res., 2003, 42, 37-50.
194. Qiao, J.; Kontoyiannis, D. P.; Wan, Z.; Li, R.; Liu, W. Antifungal activity of statins against Aspergillus species. Med. Mycol., 2007, 45, 589-593.
195. Wikhe, K.; Westermeyer, C.; Macreadie, I. G. Biological consequences of statins in Candida species and possible implications for human health. Biochem. Soc. Trans., 2007, 35, 1529-1532.
196. Macreadie, I. G.; Johnson, G.; Schlosser, T.; Macreadie, P. I. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol. Lett., 2006, 262, 9-13.
197. Westermeyer, C.; Macreadie, I. G. Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata. FEMS Yeast Res., 2007, 7, 436-441.
198. Qiao, J.; Kontoyiannis, D. P.; Wan, Z.; Li, R.; Liu, W. Antifungal activity of statins against Aspergillus species. Med. Mycol., 2007, 45, 589-593.
199. Thompson, J. N.; Huycke, M. M.; Greenfield, R. A.; Kurdgelashvili, G.; Gentry, C. A. Case-control study of statin prevention of mould infections. Mycoses, 2011, 54, e481-485.
200. Forrest, G. N.; Kopack, A. M.; Perencevich, E. N. Statins in candidemia: clinical outcomes from a matched cohort study. BMC Infect. Dis., 2010, 10, 152.
201. Nash, J. D.; Burgess, D. S.; Talbert, R. L. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J. Med. Microbiol., 2002, 51, 105-109.
202. Chin, N.; Weitzman, I.; Della-Latta, P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother., 1997, 41, 850-852.
203. Nyilasi, I.; Kocsubé, S.; Krizsán, K.; Galgóczy, L.; Pesti, M.; Papp, T.; Vágvölgyi, C. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. FEMS Microbiol. Lett., 2010, 307, 175-184.
204. Galgóczy, L.; Lukács, G.; Nyilasi, I.; Papp, T.; Vágvölgyi, C. Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes. Acta Biol. Hung., 2010, 61, 356-365.
205. Cabral, M. E.; Figueroa, L. I. C.; Fariña, J. I. Synergistic antifungal activity of statin-azole associations as witnessed by Saccharomyces cerevisiae-and Candida utilis-bioassays and ergosterol quantification. Rev. Iberoam. Micol., 2013, 30, 31-38.
206. Musiol, R.; Kowalczyk, W. Azole antimycotics -A highway to new drugs or a dead end? Curr. Med. Chem., 2012, 19, 1378-1388.
207. Krishna, G.; Ma, L.; Prasad, P.; Moton, A.; Martinho, M.; O'Mara, E. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. Expert Opin. Drug Metab. Toxicol., 2012, 8, 1-10.
208. Shaukat, A.; Benekli, M.; Vladutiu, G. D.; Slack, J. L.; Wetzler, M.; Baer, M. R. Simvastatin-fluconazole causing rhabdomyolysis. Ann. Pharmacother., 2003, 37, 1032-1035.
209. Maxa, J. L.; Melton, L. B.; Ogu, C. C.; Sills, M. N.; Limanni, A. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann. Pharmacother., 2002, 36, 820-823.
210. Zhou, Y.; Wang, G.; Li, Y.; Liu, Y.; Song, Y.; Zheng, W.; Zhang, N.; Hu, X.; Yan, S.; Jia, J. In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis. Antimicrob. Agents Chemother., 2012, 56, 3250-3260.
211. Pina-Vaz, C.; Sansonetty, F.; Rodrigues, a G.; Martinez-De-Oliveira, J.; Fonseca, a F.; Mårdh, P. a Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. J. Med. Microbiol., 2000, 49, 831-840.
212. Scott, E. M.; Tariq, V. N.; McCrory, R. M. Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Antimicrob. Agents Chemother., 1995, 39, 2610-2614.
213. Venturini, T. P.; Rossato, L.; Spader, T. B.; Tronco-Alves, G. R.; Azevedo, M. I.; Weiler, C. B.; Santurio, J. M.; Alves, S. H. In vitro synergisms obtained by amphotericin B and voriconazole associated with non-antifungal agents against Fusarium spp. Antimicrob. Agents Chemother., 2011, 71, 126-130.
214. Shalit, I.; Shadkchan, Y.; Mircus, G.; Osherov, N. In vitro synergy of caspofungin with licensed and novel antifungal drugs against clinical isolates of Fusarium spp. Med. Mycol., 2009, 47, 457-462.
215. Courchesne, W. E. Characterization of a novel, broad-based fungicidal activity for the antiarrhythmic drug amiodarone. J. Pharmacol. Exp. Ther., 2002, 300, 195-199.
216. Guo, Q.; Sun, S.; Yu, J.; Li, Y.; Cao, L. Synergistic activity of azoles with amiodarone against clinically resistant Candida albicans tested by chequerboard and time-kill methods. J. Med. Microbiol., 2008, 57, 457-462.
217. Bang, K. H.; Kim, Y. K.; Min, B. S.; Na, M. K.; Rhee, Y. H.; Lee, J. P.; Bae, K. H. Antifungal activity of magnolol and honokiol. Arch. Pharm. Res., 2000, 23, 46-49.
218. Jin, J.; Guo, N.; Zhang, J.; Ding, Y.; Tang, X.; Liang, J.; Li, L.; Deng, X.; Yu, L. The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans. Lett. Appl. Microbiol., 2010, 51, 351-357.
219. Cordeiro, R. D. A.; Astete-Medrano, D. J.; Marques, F. J. D. F.; Andrade, H. T. L.; Perdigão Neto, L. V.; Tavares, J. L.; de Lima, R. A. C.; Patoilo, K. K. N. R.; Monteiro, A. J.; Brilhante, R. S. N.; Rocha, M. F. G.; de Camargo, Z. P.; Sidrim, J. J. C. Cotrimoxazole enhances the in vitro susceptibility of Coccidioides posadasii to antifungals. Mem. Inst. Oswaldo Cruz., 2011, 106, 1045-1048.
220. Kalemba, D.; Kunicka, A. Antibacterial and antifungal properties of essential oils. Curr. Med. Chem., 2003, 10, 813-829.
221. Bassolé, I. H. N.; Juliani, H. R. Essential oils in combination and their antimicrobial properties. Molecules, 2012, 17, 3989-4006.
222. Hammer, K. A.; Carson, C. F.; Riley, T. V Antimicrobial activity of essential oils and other plant extracts. J. Appl. Microbiol., 1999, 86, 985-990.
223. Bakkali, F.; Averbeck, S.; Averbeck, D.; Idaomar, M. Biological effects of essential oils-A review. Food Chem. Toxicol., 2008, 46, 446-475.
224. Devi, K. P.; Nisha, S. A.; Sakthivel, R.; Pandian, S. K. Eugenol (an essential oil of clove) acts as an antibacterial agent against Salmonella typhi by disrupting the cellular membrane. J. Ethnopharmacol., 2010, 130, 107-115.
225. Ali, S. M.; Khan, A. A.; Ahmed, I.; Musaddiq, M.; Ahmed, K. S.; Polasa, H.; Rao, L. V.; Habibullah, C. M.; Sechi, L. A.; Ahmed, N. Antimicrobial activities of Eugenol and Cinnamaldehyde against the human gastric pathogen Helicobacter pylori. Ann. Cin. Microbiol. Antimicrob., 2005, 4, 20.
226. Kamatou, G. P.; Vermaak, I.; Viljoen, A. M. Eugenol-from the remote Maluku Islands to the international market place: A review of a remarkable and versatile molecule. Molecules, 2012, 17, 6953-6981.
227. Ahmad, A.; Khan, A.; Khan, L. A.; Manzoor, N. In vitro synergy of eugenol and methyleugenol with fluconazole against clinical Candida isolates. J. Med. Microbiol., 2010, 59, 1178-1184.
228. Shin, S.; Pyun, M.-S. Anti-Candida effects of estragole in combination with ketoconazole or amphotericin B. Phytother. Res., 2004, 18, 827-830.
229. Kim, E.; Park, I.-K. Fumigant antifungal activity of Myrtaceae essential oils and constituents from Leptospermum petersonii against three Aspergillus species. Molecules, 2012, 17, 10459-10469.
230. Demuner, A. J.; Barbosa, L. C. A.; Magalhaes, C. G.; da Silva, C. J.; Maltha, C. R. A.; Pinheiro, A. L. Seasonal variation in the chemical composition and antimicrobial activity of volatile oils of three species of Leptospermum (Myrtaceae) grown in Brazil. Molecules, 2011, 16, 1181-1191.
231. Stefanello, M. É. A.; Pascoal, A. C. R. F.; Salvador, M. J. Essential oils from neotropical Myrtaceae: chemical diversity and biological properties. Chem. Biodivers. 2011, 8, 73-94.
232. Shin, S.; Lim, S. Antifungal effects of herbal essential oils alone and in combination with ketoconazole against Trichophyton spp. J. Appl. Microbiol., 2004, 97, 1289-1296.
233. Shin, S. Anti-Aspergillus activities of plant essential oils and their combination effects with ketoconazole or amphotericin B. Arch. Pharm. Res., 2003, 26, 389-393.
234. Khan, M. S. A.; Malik, A.; Ahmad, I. Anti-candidal activity of essential oils alone and in combination with amphotericin B or fluconazole against multi-drug resistant isolates of Candida albicans. Med. Mycol., 2012, 50, 33-42.
235. Radulovi, N. S.; Deki, M. S.; Ran-elovi, P. J.; Stojanovi, N. M.; Zarubica, A. R.; Stojanovi-Radi, Z. Z. Toxic essential oils: Anxiolytic, antinociceptive and antimicrobial properties of the yarrow Achillea umbellata Sibth. et Sm. (Asteraceae) volatiles. Food Chem. Toxicol., 2012, 50, 2016-2026.
236. Pelkonen, O.; Abass, K.; Wiesner, J. Thujone and thujonecontaining herbal medicinal and botanical products: Toxicological assessment. Regul. Toxicol. Pharmacol., 2013, 65, 100-107.
237. Khosravi, a. R.; Shokri, H.; Kermani, S.; Dakhili, M.; Madani, M.; Parsa, S. Antifungal properties of Artemisia sieberi and Origanum vulgare essential oils against Candida glabrata isolates obtained from patients with vulvovaginal candidiasis. J. Med. Mycol., 2011, 21, 93-99.
238. Sonboli, A.; Babakhani, B.; Mehrabian, A. R. Antimicrobial activity of six constituents of essential oil from Salvia. Z. Naturforsch. C., 2006, 61, 160-164.
239. Rosato, A.; Vitali, C.; Gallo, D.; Balenzano, L.; Mallamaci, R. The inhibition of Candida species by selected essential oils and their synergism with amphotericin B. Phytomedicine, 2008, 15, 635-638.
240. Rosato, A.; Vitali, C.; Piarulli, M.; Mazzotta, M.; Argentieri, M. P.; Mallamaci, R. In vitro synergic efficacy of the combination of Nystatin with the essential oils of Origanum vulgare and Pelargonium graveolens against some Candida species. Phytomedicine, 2009, 16, 972-975.
241. Guo, N.; Ling, G.; Liang, X.; Jin, J.; Fan, J.; Qiu, J.; Song, Y.; Huang, N.; Wu, X.; Wang, X.; Deng, X.; Deng, X.; Yu, L. In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans. Mycoses, 2011, 54, e400-406.
242. Endo, E. H.; Cortez, D. A. G.; Ueda-Nakamura, T.; Nakamura, C. V.; Dias Filho, B. P. Potent antifungal activity of extracts and pure compound isolated from pomegranate peels and synergism with fluconazole against Candida albicans. Res. Microbiol., 2010, 161, 534-540.
243. Sharma, M.; Manoharlal, R.; Negi, A. S.; Prasad, R. Synergistic anticandidal activity of pure polyphenol curcumin I in combination with azoles and polyenes generates reactive oxygen species leading to apoptosis. FEMS Yeast Res., 2010, 10, 570-578.
244. Sharma, M.; Manoharlal, R.; Puri, N.; Prasad, R. Antifungal curcumin induces reactive oxygen species and triggers an early apoptosis but prevents hyphae development by targeting the global repressor TUP1 in Candida albicans. Biosci. Rep., 2010, 30, 391-404.
245. Sharma, M.; Manoharlal, R.; Shukla, S.; Puri, N.; Prasad, T.; Ambudkar, S. V; Prasad, R. Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals. Antimicrob. Agents Chemother., 2009, 53, 3256-3265.
246. Sanglard, D.; Odds, F. C. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis., 2002, 2, 73-85.
247. Shukla, S.; Rai, V.; Banerjee, D.; Prasad, R. Characterization of Cdr1p, a major multidrug efflux protein of Candida albicans: purified protein is amenable to intrinsic fluorescence analysis. Biochemistry, 2006, 45, 2425-2435.
248. Huang, S.; Cao, Y. Y.; Dai, B. Di; Sun, X. R.; Zhu, Z. Y.; Cao, Y. B.; Wang, Y.; Gao, P. H.; Jiang, Y. Y. In vitro synergism of fluconazole and baicalein against clinical isolates of Candida albicans resistant to fluconazole. Biol. Pharm. Bull., 2008, 31, 2234-226.
249. Aviello, G.; Abenavoli, L.; Borrelli, F.; Capasso, R.; Izzo, A. A.; Lembo, F.; Romano, B.; Capasso, F. Garlic: empiricism or science? Nat. Prod. Commun., 2009, 4, 1785-1796.
250. Tattelman, E. Health effects of garlic. Am Fam Physician, 2005, 72, 103-106.
251. Borrelli, F.; Capasso, R.; Izzo, A. A. Garlic (Allium sativum L.): Adverse effects and drug interactions in humans. Mol. Nutr. Food. Res., 2007, 51, 1386-1397.
252. Pai, S. T.; Platt, M. W. Antifungal effects of Allium sativum (garlic) extract against the Aspergillus species involved in otomycosis. Lett. Appl. Microbiol., 1995, 20, 14-18.
253. Yin, M. C.; Cheng, W. S. Inhibition of Aspergillus niger and Aspergillus flavus by some herbs and spices. J. Food Prot., 1998, 61, 123-125.
254. Yoshida, S.; Kasuga, S.; Hayashi, N.; Ushiroguchi, T.; Matsuura, H.; Nakagawa, S. Antifungal activity of ajoene derived from garlic. Appl. Env. Microbiol., 1987, 53, 615-617.
255. Shen, J.; Davis, L. E.; Wallace, J. M.; Cai, Y.; Lawson, L. D. Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans. Planta Med., 1996, 62, 415-418.
256. Guo, N.; Wu, X.; Yu, L.; Liu, J.; Meng, R.; Jin, J.; Lu, H.; Wang, X.; Yan, S.; Deng, X. In vitro and in vivo interactions between fluconazole and allicin against clinical isolates of fluconazoleresistant Candida albicans determined by alternative methods. FEMS Immunol. Med. Microbiol., 2010, 58, 193-201.
257. Khodavandi, A.; Alizadeh, F.; Aala, F.; Sekawi, Z.; Chong, P. P. In vitro investigation of antifungal activity of allicin alone and in combination with azoles against Candida species. Mycopathologia, 2010, 169, 287-295.
258. Chung, I.; Kwon, S. H.; Shim, S.-T.; Kyung, K. H. Synergistic antiyeast activity of garlic oil and allyl alcohol derived from alliin in garlic. J. Food. Sci., 2007, 72, M437-440.
259. Ledezma, E.; Apitz-Castro, R. Ajoene the main active compound of garlic (Allium sativum): A new antifungal agent. Rev. Iberoam. Micol., 2006, 23, 75-80.
260. Ledezma, E.; Maniscalchi, M. T. Sinergismo entre ajoeno y ketoconazol en aislamientos de Microsporum canis. Un estudio preliminar mediante la determinación de la concentración inhibitoria fraccional (CIF) . Rev. Iberoam. Micol., 2008, 25, 157-162.
261. Birdsall, T. C.; Kelly, G. S. Berberine-: Therapeutic potential of an alkaloid found in several medicinal plants. Altern. Med. Rev., 1997, 2, 94-103.
262. Han, Y.; Lee, J.-H. Berberine synergy with amphotericin B against disseminated candidiasis in mice. Biol. Pharm. Bull., 2005, 28, 541-544.
263. Iwazaki, R. S.; Endo, E. H.; Ueda-Nakamura, T.; Nakamura, C. V.; Garcia, L. B.; Filho, B. P. D. In vitro antifungal activity of the berberine and its synergism with fluconazole. Antonie Van Leeuwenhoek, 2010, 97, 201-205.
264. Quan, H.; Cao, Y.; Xu, Z.; Zhao, J.; Gao, P.; Qin, X.; Jiang, Y. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole. Antimicrob. Agents Chemother., 2006, 50, 1096-1099.
265. Musiol, R.; Jampilek, J.; Buchta, V.; Silva, L.; Niedbala, H.; Podeszwa, B.; Palka, A.; Majerz-Maniecka, K.; Oleksyn, B.; Polanski, J. Antifungal properties of new series of quinoline derivatives. Bioorg. Med. Chem., 2006, 14, 3592-3598.
266. Cieslik, W.; Musiol, R.; Nycz, J. E.; Jampilek, J.; Vejsova, M.; Wolff, M.; Machura, B.; Polanski, J. Contribution to investigation of antimicrobial activity of styrylquinolines. Bioorg. Med. Chem., 2012, 20, 6960-6968.
267. Wei, G.-X.; Xu, X.; Wu, C. D. In vitro synergism between berberine and miconazole against planktonic and biofilm Candida cultures. Arch. Oral Biol., 2011, 56, 565-572.
268. Sahib, N. G.; Anwar, F.; Gilani, A.-H.; Hamid, A. A.; Saari, N.; Alkharfy, K. M. Coriander (Coriandrum sativum L.): A potential source of high-value components for functional foods and nutraceuticals-A review. Phytother. Res., 2012, 10, 1439-1456.
269. Caputi, L.; Aprea, E. Use of terpenoids as natural flavouring compounds in food industry. Recent Pat. Food Nutr. Agric., 2011, 3, 9-16.
270. Del Nobile, M. a; Di Benedetto, N.; Suriano, N.; Conte, a; Lamacchia, C.; Corbo, M. R.; Sinigaglia, M. Use of natural compounds to improve the microbial stability of Amaranth-based homemade fresh pasta. Food Microbiol., 2009, 26, 151-156.
271. Antunes, M. D.; Gago, C. M.; Cavaco, A. M.; Miguel, M. G. Edible coatings enriched with essential oils and their compounds for fresh and fresh-cut fruit. Recent Pat. Food Nutr. Agric., 2012, 4, 114-122.
272. Corbo, M. R.; Speranza, B.; Filippone, a; Granatiero, S.; Conte, a; Sinigaglia, M.; Del Nobile, M. a Study on the synergic effect of natural compounds on the microbial quality decay of packed fish hamburger. Int. J. Food Microbiol., 2008, 127, 261-267.
273. Del Nobile, M. a; Corbo, M. R.; Speranza, B.; Sinigaglia, M.; Conte, a; Caroprese, M. Combined effect of MAP and active compounds on fresh blue fish burger. Int. J. Food Microbiol., 2009, 135, 281-287.
274. Cháfer, M.; Sánchez-González, L.; González-Martínez, C.; Chiralt, A. Fungal decay and shelf life of oranges coated with chitosan and bergamot, thyme, and tea tree essential oils. J. Food Sci., 2012, 77, E182-E187.
275. Camele, I.; De Feo, V.; Altieri, L.; Mancini, E.; De Martino, L.; Luigi Rana, G. An attempt of postharvest orange fruit rot control using essential oils from Mediterranean plants. J. Med. Food., 2010, 13, 1515-1523.
276. Dos Santos, N. S. T.; Athayde Aguiar, A. J. A.; de Oliveira, C. E. V.; Veríssimo de Sales, C.; de Melo E Silva, S.; Sousa da Silva, R.; Stamford, T. C. M.; de Souza, E. L. Efficacy of the application of a coating composed of chitosan and Origanum vulgare L. essential oil to control Rhizopus stolonifer and Aspergillus niger in grapes (Vitis labrusca L.). Food Microbiol., 2012, 32, 345-353.
277. Ayala-Zavala, J. F.; González-Aguilar, G. A.; Del-Toro- Sánchez, L. Enhancing safety and aroma appealing of fresh-cut fruits and vegetables using the antimicrobial and aromatic power of essential oils. J. Food Sci., 2009, 74, R84-R91.
278. Li, W.-R.; Shi, Q.-S.; Ouyang, Y.-S.; Chen, Y.-B.; Duan, S.-S. Antifungal effects of citronella oil against Aspergillus niger ATCC 16404. Appl. Microbiol Biotechnol., 2012, 16, 7483-7492.
279. Ferreira, F. D.; Kemmelmeier, C.; Arrotéia, C. C.; da Costa, C. L.; Mallmann, C. A.; Janeiro, V.; Ferreira, F. M. D.; Mossini, S. A. G.; Silva, E. L.; Machinski, M. Inhibitory effect of the essential oil of Curcuma longa L. and curcumin on aflatoxin production by Aspergillus flavus Link. Food Chem., 2013, 136, 789-793.
280. Gujral, S.; Brummer, E.; Stevens, D. A. Role of extended culture time on synergy of fluconazole and human monocyte-derived macrophages in clearing Candida albicans. J. Infect. Dis., 1996, 174, 888-890.
281. Kontoyiannis, D. P.; Lewis, R. E. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist. Updat., 2003, 6, 257-269.
282. Ostrosky-Zeichner, L. Combination antifungal therapy: A critical review of the evidence. Clin. Microbiol. Infect., 2008, 14 Suppl 4, 65-70.
283. Matsuda, T.; Koreeda, Y.; Mataki, H.; Taira, T.; Noma, S.; Higashimoto, I. A case of Aspergillus empyema successfully treated with combination therapy of voriconazole and micafungin: excellent penetration of voriconazole and micafungin into pleural fluid. Intern. Med., 2010, 49, 1163-1169.
284. Pachl, J.; Svoboda, P.; Vandewoude, K.; Hoven, B. Van Der; Spronk, P.; Masterson, G.; Malbrain, M.; Aoun, M.; Garbino, J.; Takala, J.; Drgona, L.; Burnie, J.; Matthews, R.; Invasive, M.; Study, C. A randomized, blinded, multicenter trial of lipidassociated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in. Clin. Infect. Dis., 2006, 42, 1404-1413.
285. Matthews, R. C.; Rigg, G.; Hodgetts, S.; Carter, T.; Chapman, C.; Gregory, C.; Illidge, C.; Burnie, J. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother., 2003, 47, 2208-2216.
286. Cowen, L. E.; Lindquist, S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science, 2005, 309, 2185-2189.
287. Rex, J. H.; Pappas, P. G.; Karchmer, A. W.; Sobel, J.; Edwards, J. E.; Hadley, S.; Brass, C.; Vazquez, J. A.; Chapman, S. W.; Horowitz, H. W.; Zervos, M.; McKinsey, D.; Lee, J.; Babinchak, T.; Bradsher, R. W.; Cleary, J. D.; Cohen, D. M.; Danziger, L.; Goldman, M.; Goodman, J.; Hilton, E.; Hyslop, N. E.; Kett, D. H.; Lutz, J.; Rubin, R. H.; Scheld, W. M.; Schuster, M.; Simmons, B.; Stein, D. K.; Washburn, R. G.; Mautner, L.; Chu, T.; Panzer, H.; Rosenstein, R. B.; Booth, J. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin. Infect Dis., 2003, 36, 1221-1228.
288. Baran, R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br. J. Dermatol., 2001, 145 Suppl, 15-19.
289. Baran, R.; Feuilhade, M.; Combernale, P.; Datry, A.; Goettmann, S.; Pietrini, P.; Viguie, C.; Badillet, G.; Larnier, C.; Czernielewski, J. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region. Br. J. Dermatol., 2000, 142, 1177-1183.
290. Baran, R.; Sigurgeirsson, B.; de Berker, D.; Kaufmann, R.; Lecha, M.; Faergemann, J.; Kerrouche, N.; Sidou, F. A multicentre, randomized, controlled study of the efficacy, safety and costeffectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix invol. Br. J. Dermatol., 2007, 157, 149-157.
291. Jaiswal, A.; Sharma, R. P.; Garg, A. P. An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. Indian. J. Dermatol. Venereol. Leprol., 2007, 73, 393-396.
292. Lecha, M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br. J. Dermatol., 2001, 145 Suppl, 21-26.
293. Rigopoulos, D.; Katoulis, A. C.; Ioannides, D.; Georgala, S.; Kalogeromitros, D.; Bolbasis, I.; Karistinou, A.; Christofidou, E.; Polydorou, D.; Balkou, P.; Fragouli, E.; Katsambas, A. D. A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br. J. Dermatol., 2003, 149, 151-156.